Figure 1A

Figure 1B

Figure 1C

CAT GAG AAA ACG CCA GTA AGT GAC AGA GTC ACA AAA TGC TGC ACA GAG TCC 1440 H E K T P V S D R V T K C C T E S 480

1381 TGT GTG TTG

1561 AGA CAA ATC AAG AAA CAA ACT GCA CTT GTT GAG CTT GTG AAA CAC AAG GCA ACA 1620 521 R Q I K R Q T A L V E L V K H K P K A T 540 TTT GCC GAG GGT AAA AAA CTT GTT GCT GCA AGT CAA 1740 F A E E G K K L V A A S Q 580 GAT GAA ACA TAC GTT CCC AAA 1500 D E T Y V P K 500 TGC ACA CTT TCT GAG AAG GAG 1560 C T L S E K E 520 ATG GAT GAT TTC GCA GCT TTT GTA GAG AAG TGC TGC AAG 1680 M D D F A A F V E K C C K 560 . 1741 GCT GCC TTA GGC TTA TAA CAT CTA CAT TTA AAA GCA TCT CAG 1782 581 A A L G L * TTC ACC TTC CAT GCA GAT ATA F T F H A D I 1441 TTG GTG AAC AGG CGA CCA TGC TTT TCA GCT CTG GAA GTC 481 L V N R R P C F S A L E V CTG AAA GCT GTT L K A V 1681 GCT GAC GAT AAG GAG ACC TGC 561 A D D K E T C ACA 1501 GAG TTT AAT GCT GAA 501 E F N A E 1621 AAA GAG CAA 541 K E Q

Figure 1D




Figure 2




Figure 3

Comparison of the effect of Epo albumin fusion proteins CID 1981, CID 1966, and recombinant human Epo on the proliferation of TF-1 cells.




Figure 4

Comparison of the effect of recombinant human Epo and Epo albumin fusion proteins on the % change in hematocrit from day 0 to day 7: dose-response analysis




Figure 5

Dose schedule: Comparison of the effect of Epo albumin fusion proteins on % change in hematocrit





Figure 6A

Dose schedule: Comparison of the effect of Epo albumin Fusion proteins on % change in hematocrit



% change in hematocrit: day 0 to day 14

Figure 6B

Comparison of the effect of Epo albumin fusion proteins and recombinant human Epo on the proliferation of TF-1 cells




Figure 7

Comparison of the effect of recombinant human Epo and Epo albumin fusion protein encoded by CID 1997 on the % change in hematocrit from day 0 to day 8: dose-response analysis




Figure 8

Activity of IL-2 albumin fusion protein encoded by CID 1812 in the CTLL-2 proliferation assay




Figure 9

Eff ct of IL2 albumin fusion protein ncoded by CID 1812 on RENCA tumor growth in BALB/c mice: Day 21





Figure 10

Respons of NFS-60 c IIs to GCSF albumin fusion proteins (supernatants)



GCSF albumin fusion protein supernatants (dilution)

Figure 11

Effects of GCSF albumin fusion protein (GCSF fusion) on total white blood cell count (WBC)




Figure 12

Dos r spons of IFNb albumin fusion proteins




Figure 13




Figure 14

Inhibition of proliferation of HS294T melanoma cells by IFNa albumin fusion protein




Figure 15

SEAP activation with IFNa albumin fusion proteins




Figure 16




Figure 17

Wigot Alluson WHOL UINSU NUL UINSU Glucose uptake in 3T3 L1 adipocytes MIDOL (QLE) SSS VSH NIGOLOGE SASSIA Muol Osees Sassons Æ 320 300 250 200 150 <u>8</u> 20 Change over basal glucose uptake (%)

FIGURE 18




Figure 19